J&J looks to toss its SGLT2 hat in the ring for two types of heart failure

In the last year, two SGLT2 inhibitors — initially developed to treat diabetes — have snagged approvals in the heart failure space. Now Johnson & Johnson is jumping on the bandwagon, reading out positive Phase III results for its own SGLT2 drug Invokana.